Objective: This systematic review assessed the available published evidence on the efficacy and safety of using trigger point injection (TPI) to treat patients with chronic non-malignant musculoskeletal pain that had persisted for at least 3 months.

Methods: All published systematic reviews or randomized controlled trials detailing the use of TPI in patients with chronic, non-malignant musculoskeletal pain (persisting for >3 months) were identified by systematically searching literature databases and the Websites of various health technology assessment agencies, research registers, and guidelines sites up to July 2006.

Results: Although no systematic reviews were identified, 15 peer-reviewed randomized controlled trials met the inclusion criteria. However, deficiencies in reporting, small sample sizes, and marked inter-study heterogeneity precluded a definitive synthesis of the data. TPI is a safe procedure when used by clinicians with appropriate expertise and training. It relieved symptoms when used as a sole treatment for patients with chronic head, neck, shoulder, and back pain or whiplash syndrome, regardless of the injectant used, and may be a useful adjunct to intra-articular injection in the treatment of osteoarthritis pain. Although the addition of TPI to stretching exercises augments treatment outcomes, this was also true of other therapies such as ultrasound and laser.

Conclusion: The efficacy of TPI is no more certain than it was a decade ago as, overall, there is no clear evidence of either benefit or ineffectiveness. The only advantage of injecting anesthetic into trigger points may be to reduce the pain of the needling process, which may not be an insignificant benefit.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1526-4637.2008.00526.xDOI Listing

Publication Analysis

Top Keywords

chronic non-malignant
12
non-malignant musculoskeletal
12
musculoskeletal pain
12
patients chronic
12
trigger point
8
systematic review
8
systematic reviews
8
randomized controlled
8
controlled trials
8
pain
6

Similar Publications

Myeloid chimerism better reflects donor stem cell engraftment than whole-blood chimerism in assessing graft function following allogeneic hematopoietic stem cell transplant (HCT). We describe our experience with 130 patients aged younger than 18 years, treated with allogeneic HCT using bone marrow or PBSC from HLA-matched donors for non-malignant diseases, whose pre-transplant conditioning therapy included alemtuzumab and who were monitored with lineage-specific chimerism after transplant. At 6 years post-transplant, overall survival (OS) was 91.

View Article and Find Full Text PDF

Diagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update.

Diagnostics (Basel)

December 2024

Unit of Clinical Pathology, Department of Medical and Surgical Sciences, University of Foggia, University Hospital "Policlinico Riuniti", Viale Luigi Pinto, 71122 Foggia, Italy.

Monoclonal gammopathy of renal significance (MGRS) refers to a group of renal disorders caused by a monoclonal immunoglobulin (MIg), secreted by a non-malignant B-cell clone. Unlike overt multiple myeloma or B-cell proliferation, MGRS does not meet those diagnostic criteria. However, it is associated with significant morbidity, due to severe renal, and sometimes systemic, lesions induced by the MIg.

View Article and Find Full Text PDF
Article Synopsis
  • Allogeneic haematopoietic stem cell transplantation (alloHSCT) shows high survival rates (90% overall survival) in adolescents and adults with severe inborn errors of immunity (IEI), as assessed in a study of 82 patients.
  • The study found that pre-transplant immune dysregulation (measured by the IDDA v2.1 score) and the haematopoietic cell transplantation comorbidity index (HCT-CI) score significantly affected transplant outcomes, including overall survival and event-free survival.
  • Notably, a portion of patients with a high IDDA v2.1 score and low HCT-CI score indicates that existing risk assessments may underestimate the risks of alloHSCT, highlighting
View Article and Find Full Text PDF

CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.

Front Immunol

January 2025

Innovation & Research Department, OriCell Therapeutics Co. Ltd., Shanghai, China.

Article Synopsis
  • Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune disorders that lead to chronic inflammation and organ damage, with current treatments lacking a definitive cure.
  • Recent studies suggest that chimeric antigen receptor T-cell (CAR-T) therapy, which has been effective in B-cell cancers, may also be a breakthrough treatment for SLE.
  • This paper analyzes CAR-T therapy's mechanisms, clinical data on its efficacy in targeting B-cells for SLE treatment, and emphasizes the need for further research in improving therapeutic strategies for these complex conditions.
View Article and Find Full Text PDF

Background: Patients with advanced chronic non-malignant conditions often experience significant symptom burden. Therefore, overcoming barriers to interprofessional collaboration between general practitioners (GPs) and specialist palliative home care (SPHC) teams is essential to facilitate the timely integration of palliative care elements. The KOPAL trial aimed to examine the impact of case conferences between GPs and SPHC teams on symptom burden and pain in patients with advanced chronic heart failure, chronic obstructive pulmonary disease, and dementia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!